The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson’s disease
Objective: Objective: The aim of this paper is to present the result of the whole body screening of Lewy body pathology by Brain Bank for…Falls in Mild Cognitive Impairment with Lewy bodies (MCI-LB).
Objective: to identify clinical, physical activity and mobility measures that differentiate patients with mild cognitive impairment with Lewy bodies (MCI-LB) fallers and non-fallers from cognitively…A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…In vivo positive amyloid PET in a patient with PDD, always reliable?
Objective: To describe a singular case of an early-onset Parkinson disease (PD) patient with PD dementia who presented in vivo positive 18 F-Flutebetamol PET but…Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia
Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…Health status of Lewy Body Dementia caregivers predicts psychological response to peer mentoring intervention
Objective: To understand how caregiver health status influences response to a peer mentoring intervention in caregivers of individuals with Lewy Body Dementia (LBD). Background: Caregiving…Sex differences for clinicopathological correlations in people with Lewy body pathology
Objective: To determine sex-specific clinical correlations of different Lewy body (LB), Alzheimer’s disease (AD) pathology staging and nigral neuron loss levels in people with LB…Impact of the severity of Parkinson’s disease on skin elasticity
Objective: To investigate changes in skin elasticity according to the severity of symptoms of Parkinson's disease. Background: Parkinson's disease (PD) is a neurodegenerative disease caused…Recruiting people at risk of Parkinson’s disease: comparative data from PPMI Online and HeBA Kassel
Objective: To compare a US- and Germany-based staged screening process to identify people at risk of developing Parkinson’s disease (PD). Background: The Parkinson’s Progression Marker…Blaming neuromelanin for Parkinson’s disease: time-dependent tyrosinase overexpression drives endogenous synucleinopathy in non-human primates
Objective: Development and characterization of a novel non-human primate model of Parkinson’s disease based on the AAV-mediated forced expression of human tyrosinase Background: Although neuromelanin…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »